Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nagi Bioscience has developed SydLab™ One—an automated "Organism-on-Chip" platform that enables high-throughput drug and chemical screening using C. elegans nematodes as whole-organism models. This technology provides early-stage toxicology and efficacy data at unprecedented scale and reproducibility while reducing reliance on vertebrate animal models. The company serves biopharma, biotech, academia, agro-science/nutrition/cosmetics industries with both product sales and contract laboratory services. Over a decade of R&D underpins their approach.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nagi Bioscience.